Citations

Clear

7551 citation(s) found for "Ho, Matthew".

Late outcomes of adult survivors of childhood non‐Hodgkin lymphoma: A report from the St. Jude Lifetime Cohort Study
Ehrhardt, Matthew J. , Sandlund, John T., Zhang, Nan , Liu, Wei , Ness, Kirsten K. , Bhakta, Nickhill , Chemaitilly, Wassim , Krull, Kevin R. , Brinkman, Tara M. , Crom, Deborah B., Kun, Larry E. , Kaste, Sue C. , Armstrong, Gregory T. , Srivastava, Kumar , Mulrooney, Daniel A. , Green, Daniel M. , Robison, Leslie L. , Hudson, Melissa M. , Mulrooney, Daniel A , Ness, Kirsten K , Bhakta, Nickhill

Mayo Clinic

Pediatric Blood & Cancer | November 16, 2016 | Volume: 64 | Issue: 6 | Pages: No page available

10.1002/pbc.26338 | PMID 27860222 Get It

AbstractBackgroundSurvivors of childhood non‐Hodgkin lymphoma (NHL) are at increased risk for chronic health conditions. The objective of this study was to characterize health conditions, neurocognitive function, and physical performance among a clinically evaluated cohort of 200 childhood NHL survivors.MethodChronic health and neurocognitive conditions were graded as per a modified version of the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) and impaired physical function defined as performance < 10th percentile of normative data. Multivariable regression was used to investigate associations between sociodemographic characteristics, therapeutic exposures, and outcomes.ResultsSurvivors were a median age of 10 years (range 1–19) at diagnosis and 34 years (range 20–58) at evaluation. Eighty‐eight (44%) received radiation, 46 (23%) cranial radiation, and 69 (35%) high‐dose methotrexate. Most prevalent CTCAE Grades 3–4 (severe life‐threatening) conditions were obesity (35%), hypertension (9%), and impairment of executive function (13%), attention (9%), and memory (4%). Many had impaired strength (48%), flexibility (39%), muscular endurance (36%), and mobility (36%). Demographic and treatment‐related factors were associated with the development of individual chronic diseases and functional deficits.ConclusionsClinical evaluation identified a high prevalence of chronic health conditions, neurocognitive deficits, and performance limitations in childhood NHL survivors.
Oncolytic reovirus as a combined antiviral and anti-tumour agent for the treatment of liver cancer
Samson, Adel , Bentham, Matthew, Scott, Karen J. , Nuovo, Gerard J., Bloy, Abigail, Appleton, Elizabeth , Adair, Robert A, Dave, Rajiv , Toogood, Giles J. , Nagamori, Seishi, Coffey, Matthew, Vile, Richard G. , Harrington, Kevin J. , Selby, Peter J. , Errington‐Mais, Fiona , Melcher, Alan , Griffin, Stephen , Griffin, Stephen , Adair, Robert A, Peckham-Cooper, Adam , Errington-Mais, Fiona , Melcher, Alan A , Harrington, Kevin , Dave, Rajiv V , Appleton, Elizabeth

Mayo Clinic

Gut | November 16, 2016 | Volume: 67 | Issue: 3 | Pages: 562-573

10.1136/gutjnl-2016-312009 | PMID 27902444 Get It

Objective Oncolytic viruses (OVs) represent promising, proinflammatory cancer treatments. Here, we explored whether OV-induced innate immune responses could simultaneously inhibit HCV while suppressing hepatocellular carcinoma (HCC). Furthermore, we extended this exemplar to other models of virus-associated cancer. Design and results Clinical grade oncolytic orthoreovirus (Reo) elicited innate immune activation within primary human liver tissue in the absence of cytotoxicity and independently of viral genome replication. As well as achieving therapy in preclinical models of HCC through the activation of innate degranulating immune cells, Reo-induced cytokine responses efficiently suppressed HCV replication both in vitro and in vivo. Furthermore, Reo-induced innate responses were also effective against models of HBV-associated HCC, as well as an alternative endogenous model of Epstein–Barr virus-associated lymphoma. Interestingly, Reo appeared superior to the majority of OVs in its ability to elicit innate inflammatory responses from primary liver tissue. Conclusions We propose that Reo and other select proinflammatory OV may be used in the treatment of multiple cancers associated with oncogenic virus infections, simultaneously reducing both virus-associated oncogenic drive and tumour burden. In the case of HCV-associated HCC (HCV-HCC), Reo should be considered as an alternative agent to supplement and support current HCV-HCC therapies, particularly in those countries where access to new HCV antiviral treatments may be limited.
Magnetic resonance elastography (MRE) of the human brain: technique, findings and clinical applications
Hiscox, Lucy V. , McGarry, Matt D J, Starr, John M. , Roberts, Neil , Johnson, Curtis L. , Barnhill, Eric , McGarry, Matthew D. J. , Huston, John , Beek, Edwin J.R. van

Mayo Clinic

Physics in Medicine & Biology | November 15, 2016 | Volume: 61 | Issue: 24 | Pages: R401-R437

10.1088/0031-9155/61/24/r401 | PMID 27845941 Get It

Abstract Neurological disorders are one of the most important public health concerns in developed countries. Established brain imaging techniques such as magnetic resonance imaging (MRI) and x-ray computerised tomography (CT) have been essential in the identification and diagnosis of a wide range of disorders, although usually are insufficient in sensitivity for detecting subtle pathological alterations to the brain prior to the onset of clinical symptoms—at a time when prognosis for treatment is more favourable. The mechanical properties of biological tissue provide information related to the strength and integrity of the cellular microstructure. In recent years, mechanical properties of the brain have been visualised and measured non-invasively with magnetic resonance elastography (MRE), a particularly sensitive medical imaging technique that may increase the potential for early diagnosis. This review begins with an introduction to the various methods used for the acquisition and analysis of MRE data. A systematic literature search is then conducted to identify studies that have specifically utilised MRE to investigate the human brain. Through the conversion of MRE-derived measurements to shear stiffness (kPa) and, where possible, the loss tangent (rad), a summary of results for global brain tissue and grey and white matter across studies is provided for healthy participants, as potential baseline values to be used in future clinical investigations. In addition, the extent to which MRE has revealed significant alterations to the brain in patients with neurological disorders is assessed and discussed in terms of known pathophysiology. The review concludes by predicting the trends for future MRE research and applications in neuroscience.
Consensus Statement of the American Academy of Sleep Medicine on the Recommended Amount of Sleep for Healthy Children: Methodology and Discussion
Paruthi, Shalini, Brooks, Lee J., D’Ambrosio, Carolyn, Hall, Wendy A. , Kotagal, Suresh , Lloyd, Robin M. , Malow, Beth A. , Nichols, Cynthia , Quan, Stuart F. , Rosen, Carol L. , Troester, Matthew M., Wise, Merrill S. , Maski, Kiran

Mayo Clinic

Journal of Clinical Sleep Medicine | November 14, 2016 | Volume: 12 | Issue: 11 | Pages: 1549-1561

10.5664/jcsm.6288 | PMID 27707447 Get It

The Cost-Effectiveness of Antibiotic Prophylaxis for Patients at Risk of Infective Endocarditis
Franklin, Matthew , Wailoo, Allan , Jones, Simon , Prendergast, Bernard , Lockhart, Peter B. , Thornhill, Martin H. , Dayer, Mark J, Dayer, Mark , Baddour, Larry M. , Thornhill, M H

Mayo Clinic

Circulation | November 13, 2016 | Volume: 134 | Issue: 20 | Pages: 1568-1578

10.1161/circulationaha.116.022047 | PMID 27840334 Get It

Background: In March 2008, the National Institute for Health and Care Excellence recommended stopping antibiotic prophylaxis (AP) for those at risk of infective endocarditis (IE) undergoing dental procedures in the United Kingdom, citing a lack of evidence of efficacy and cost-effectiveness. We have performed a new economic evaluation of AP on the basis of contemporary estimates of efficacy, adverse events, and resource implications. Methods: A decision analytic cost-effectiveness model was used. Health service costs and benefits (measured as quality-adjusted life-years) were estimated. Rates of IE before and after the National Institute for Health and Care Excellence guidance were available to estimate prophylactic efficacy. AP adverse event rates were derived from recent UK data, and resource implications were based on English Hospital Episode Statistics. Results: AP was less costly and more effective than no AP for all patients at risk of IE. The results are sensitive to AP efficacy, but efficacy would have to be substantially lower for AP not to be cost-effective. AP was even more cost-effective in patients at high risk of IE. Only a marginal reduction in annual IE rates (1.44 cases in high-risk and 33 cases in all at-risk patients) would be required for AP to be considered cost-effective at £20 000 ($26 600) per quality-adjusted life-year. Annual cost savings of £5.5 to £8.2 million ($7.3–$10.9 million) and health gains >2600 quality-adjusted life-years could be achieved from reinstating AP in England. Conclusions: AP is cost-effective for preventing IE, particularly in those at high risk. These findings support the cost-effectiveness of guidelines recommending AP use in high-risk individuals.
Persistence and switching patterns of oral migraine prophylactic medications among patients with chronic migraine: A retrospective claims analysis
Hepp, Zsolt, Varon, Sepideh F., Chia, Jenny , Matthew, Nitya, Gillard, Patrick, Hansen, Ryan N. , Devine, Emily Beth , Dodick, David W.

Mayo Clinic

Cephalalgia | November 11, 2016 | Volume: 37 | Issue: 5 | Pages: 470-485

10.1177/0333102416678382 | PMID 27837173 Get It

Background Migraine prevention guidelines recommend oral prophylactic medications for patients with frequent headache. This study examined oral migraine preventive medication (OMPM) treatment patterns by evaluating medication persistence, switching, and re-initiation in patients with chronic migraine (CM). Methods A retrospective US claims analysis (Truven Health MarketScan® Databases) evaluated patients ≥18 years old diagnosed with CM who had initiated an OMPM between 1 January, 2008 and 30 September, 2012. Treatment persistence was measured at six and 12 months’ follow-up. Time-to-discontinuation was assessed for each OMPM and compared using Cox regression models. Among those who discontinued, the proportion that switched OMPMs within 60 days or re-initiated treatment between 61 to 365 days, and their associated persistence rates, were also assessed. Results A total of 8707 patients met the inclusion/exclusion criteria. Persistence to the initial OMPM was 25% at six months and 14% at 12 months. Based on Kaplan-Meier curves, a sharp decline of patients discontinuing was observed by 30 days, and approximately half discontinued by 60 days. Similar trends in time-to-discontinuation were seen following the second or third OMPM. Amitriptyline, gabapentin, and nortriptyline had significantly higher likelihood of non-persistence compared with topiramate. Among patients who discontinued, 23% switched to another prophylactic and 41% re-initiated therapy within one year. Among patients who switched, persistence was between 10 to 13% and among re-initiated patients, persistence was between 4 to 8% at 12 months. Conclusions Persistence to OMPMs is poor at six months and declines further by 12 months. Switching between OMPMs is common, but results indicate that persistence worsens as patients cycle through various OMPMs.
What is the lifetime risk of revision for patients undergoing total hip arthroplasty?
Roth, Philipp von , Harmsen, William S. , Berry, Daniel J. , Abdel, Matthew P. , Berry, Daniel J

Mayo Clinic

The Bone & Joint Journal | November 1, 2016 | Volume: 98-B | Issue: 11 | Pages: 1436-1440

10.1302/0301-620x.98b11.bjj-2016-0337.r1 | PMID 27803217 Get It

AimsThe purpose of this study was to determine the lifetime risk of revision surgery for patients undergoing Charnley cemented total hip arthroplasty (THA), with 40-year follow up, using death as a competing risk.Materials and MethodsWe retrospectively reviewed 2000 cemented Charnley THAs, with 51 living hips available at 40 years.ResultsThe cumulative risk of revision or removal for any reason was 13% (95% confidence interval (CI) 12 to 15). Patients aged under 50 years at the time of surgery had a 35% (95% CI 28 to 42) risk of revision or removal for any reason (Hazard Ratio (HR) 3.6; 95% CI 2.5 to 5.2; p < 0.001), patients 50 to 59 years old had a 20% risk (95% CI 16 to 24) (HR 2.1; 95% CI 1.5 to 2.8; p < 0.0001), patients aged 60 to 69 years had a 9% risk (95% CI 7 to 11) (reference point), and patients ≥ 70 years old had a 5% risk (95% CI 4 to 7) (HR 0.96; 95% CI 0.6 to 1.5; p = 0.86) during their lifetime. Men had a higher risk of revision or removal for any reason (HR 2.1; 95% CI 1.7 to 2.7; p < 0.001).ConclusionWith almost all the patients in this series followed up till either death or revision, we have been able to develop a ‘rule of thumb’ for lifetime likelihood of revision or implant removal for the Charnley THA: one in three for patients < 50 years, one in five for patients 50 to 59 years, one in ten for patients 60 to 69 years, and one in 20 for patients ≥ 70 years. The results provide a benchmark for comparison of outcomes, for the newer designs of THA. Cite this article: Bone Joint J 2016;98-B:1436–40.
The monitoring of activity at home after total hip arthroplasty
Toogood, Paul , Spear, Joshua A. , Cook, S. M., Taunton, Michael J. , Abdel, Matthew P. , Cook, David J. , Taunton, Michael J

Mayo Clinic

The Bone & Joint Journal | November 1, 2016 | Volume: 98-B | Issue: 11 | Pages: 1450-1454

10.1302/0301-620x.98b11.bjj-2016-0194.r1 | PMID 27803219 Get It

Aims Total hip arthroplasty (THA) has well known subjective benefits, but little is known objectively about the recovery of mobility in the early post-operative period. Patients and Methods A total of 33 patients aged > 60 years who underwent elective primary THA had their activity monitored for 30 days post-operatively using an at-home (Fitbit) ankle accelerometer. Their mean age was 70.7 years (61 to 86); 15 (45.5%) were female. The rate of compliance and the mean level of activity were determined. Comparisons between subgroups based on age, body mass index (BMI), surgical approach, and the destination of the patients when discharged were also performed. Results The mean compliance over the 30 days was 26.7 days (16 to 30; 89%) of use. The mean number of steps increased from 235 (5 to 1152) to 2563 (87 to 7280) (p < 0.001) between the first and the 30th post-operative day. Age < 70 years and an anterior surgical approach were significantly associated with higher levels of activity (1600 to 2400 (p = 0.016 to 0.031) and 1000 to 1800 (p = 0.017 to 0.037) more steps per day, respectively) between the second and the fourth week post-operatively. There was also a trend towards higher levels of activity in those who were discharged to their home rather than to a nursing facility (a mean of 1500 more steps per day, p = 0.02). BMI greater or less than 30 kg/m 2 was not predictive of activity (p = 0.45 to 0.98). Conclusion At-home remote mobility monitoring using existing commercially available technology is feasible in patients who have undergone THA. It showed a clear trend towards increased activity with the passage of time. Additionally, the remote device was able to detect differences in levels of activity clearly between patients in relation to variables of interest including age, BMI, surgical approach, and the destination of the patient at the time of discharge from hospital. Such monitoring may allow for the early identification and targeted intervention in patients who recover slowly. Cite this article: Bone Joint J 2016;98-B:1450–4.
A comparison of tissue-based and recombinant protein–based assays for detecting PCA-Tr/DNER-IgG
Alfugham, Nora, Roforth, Matthew M., Komorowski, Lars , Ott, Anthonina, Meyer, Wolfgang , Probst, Christian , Lennon, Vanda A. , Pittock, Sean J. , McKeon, Andrew , Roforth, Matthew, Pittock, S J , McKeon, Andrew

Mayo Clinic

Neurology Neuroimmunology & Neuroinflammation | October 29, 2016 | Volume: 3 | Issue: 6 | Pages: No page available

10.1212/nxi.0000000000000294 | PMID 27844036 Get It